ArticleArthritis research & therapy2018
Metabolomic alterations associated with Behçet's disease.
Article in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Finding the Needle in the Haystack: Serological and Urinary Biomarkers in Behçet's Disease: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Plasma Lipidomic Remodeling in Behçet's Disease Reveals Alterations Associated with Vascular Involvement.Metabolites · 2026Article
- Identification of a diagnostic metabolomic fingerprint in plasma for eosinophilic granulomatosis with polyangiitis.PloS one · 2026Article
- Predicting response to infliximab and interferon-α in Behçet's syndrome: An exploratory analysis from the BIO-BEHÇET'S randomized controlled trial.Rheumatology and immunology research · 2025Article
- Altered polyunsaturated fatty acids and oxylipins profile in Behçet's disease.The Korean journal of internal medicine · 2025Article
- Specific plasma metabolite profile in intestinal Behçet's syndrome.Orphanet journal of rare diseases · 2025Article
- Gut microbiome dysregulation in noninfectious uveitis.Frontiers in immunology · 2025Review
- Differential intestinal microbes and metabolites between Behcet's uveitis and Fuchs syndrome.Heliyon · 2024Article
- TNF inhibitors target a mevalonate metabolite/TRPM2/calcium signaling axis in neutrophils to dampen vasculitis in Behçet's disease.Nature communications · 2024Article
- Advances in Mass Spectrometry-Based Blood Metabolomics Profiling for Non-Cancer Diseases: A Comprehensive Review.Metabolites · 2024Review
- Comparative Metabolomic Profiles of Vascular Involvement in Behçet's Disease.European journal of rheumatology · 2023Article
- Integrative metabolomics of plasma and PBMCs identifies distinctive metabolic signatures in Behçet's disease.Arthritis research & therapy · 2023Article
- The role of miRNAs in Behçet's disease.Frontiers in immunology · 2023Review
- A Contemporary Review of Behcet's Syndrome.Clinical reviews in allergy & immunology · 2021Review
- Serum Metabolomic Alterations Associated with Cesium-137 Internal Emitter Delivered in Various Dose Rates.Metabolites · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundThe diagnosis of Behçet's disease (BD) remains challenging due to the lack of diagnostic biomarkers. This study aims to identify potential serum metabolites associated with BD and its disease activity.
methodsMedical records and serum samples of 24 pretreated BD patients, 12 post-treated BD patients, and age-matched healthy controls (HC) were collected for metabolomics and lipidomics profiling using UPLC-QTOF-MS and UPLC-QTOF-MS
resultsUnsupervised principal component analysis (PCA) showed a clear separation of metabolomics profiles of BD patients from HC. Statistical analysis of the data revealed differential metabolites between BD patients and HC. The serum levels of some phosphatidylcholines (PCs) were found to be significantly lower in BD patients, while the levels of several polyunsaturated fatty acids (PUFAs) were increased markedly in the BD group compared with HC. Furthermore, the serum level of two omega-6 PUFAs, linoleic acid (LA) and arachidonic acid (AA), were dramatically decreased in patients with remission. A validation cohort confirmed that the serum LA and AA levels in BD patients were significantly higher than those in HC and patients with RA, SLE, TA, and CD. In addition, receiver operating characteristic (ROC) analysis indicated good sensitivity and specificity.
conclusionsThe serum metabolomics profiles in BD patients are altered. Serum LA and AA are promising diagnostic biomarkers for BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.